<p>Sun Pharmaceutical Industries Limited announced that it has launched FluGuard® (Favipiravir 200 mg) at Rs 35 per tablet, for the treatment of mild to moderate cases of Covid-19 in India. Favipiravir is the only oral anti-viral treatment approved in India for the potential treatment of patients with mild to moderate Covid-19 disease.</p>.<p><strong><a href="https://www.deccanherald.com/national/coronavirus-news-live-updates-west-bengal-records-2261-fresh-covid-19-cases-864013.html" target="_blank">Track live updates on coronavirus here</a></strong></p>.<p>Commenting on the launch, Kirti Ganorkar, CEO of India Business, Sun Pharma said, “With over 50,000 Covid-19 cases being reported daily in India, there is an urgent need to provide more treatment options to healthcare professionals. We are launching FluGuard® at an economical price to make the drug accessible to more and more patients thereby reducing their financial burden. This is in line with our continuous efforts to support India’s pandemic response.”<br /> <br />The company will work closely with the government and medical community to ensure availability of FluGuard® to patients across the country. The stocks of FluGuard® will be available in the market from this week.</p>
<p>Sun Pharmaceutical Industries Limited announced that it has launched FluGuard® (Favipiravir 200 mg) at Rs 35 per tablet, for the treatment of mild to moderate cases of Covid-19 in India. Favipiravir is the only oral anti-viral treatment approved in India for the potential treatment of patients with mild to moderate Covid-19 disease.</p>.<p><strong><a href="https://www.deccanherald.com/national/coronavirus-news-live-updates-west-bengal-records-2261-fresh-covid-19-cases-864013.html" target="_blank">Track live updates on coronavirus here</a></strong></p>.<p>Commenting on the launch, Kirti Ganorkar, CEO of India Business, Sun Pharma said, “With over 50,000 Covid-19 cases being reported daily in India, there is an urgent need to provide more treatment options to healthcare professionals. We are launching FluGuard® at an economical price to make the drug accessible to more and more patients thereby reducing their financial burden. This is in line with our continuous efforts to support India’s pandemic response.”<br /> <br />The company will work closely with the government and medical community to ensure availability of FluGuard® to patients across the country. The stocks of FluGuard® will be available in the market from this week.</p>
